WO2018198101A2 - Processes for the preparation of crystalline form of eluxadoline - Google Patents

Processes for the preparation of crystalline form of eluxadoline Download PDF

Info

Publication number
WO2018198101A2
WO2018198101A2 PCT/IB2018/053134 IB2018053134W WO2018198101A2 WO 2018198101 A2 WO2018198101 A2 WO 2018198101A2 IB 2018053134 W IB2018053134 W IB 2018053134W WO 2018198101 A2 WO2018198101 A2 WO 2018198101A2
Authority
WO
WIPO (PCT)
Prior art keywords
eluxadoline
crystalline form
obtain
reaction mass
xrpd
Prior art date
Application number
PCT/IB2018/053134
Other languages
French (fr)
Other versions
WO2018198101A3 (en
Inventor
Sriram Hari MOHAN
Mukesh Kumar Madhra
Ketan Vithalbhai HIRPARA
Original Assignee
Sun Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IN201711014592 priority Critical
Priority to IN201711014592 priority
Application filed by Sun Pharmaceutical Industries Limited filed Critical Sun Pharmaceutical Industries Limited
Publication of WO2018198101A2 publication Critical patent/WO2018198101A2/en
Publication of WO2018198101A3 publication Critical patent/WO2018198101A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Abstract

The present invention relates to processes for the preparation of a crystalline form of eluxadoline.

Description

PROCESSES FOR THE PREPARATION OF CRYSTALLINE FORM

OF ELUXADOLINE

Field of the Invention

The present invention relates to processes for the preparation of a crystalline form of eluxadoline.

Background of the Invention

Eluxadoline chemically is 5-[[[(25)-2-amino-3-[4-(aminocarbonyl)-2, 6- dimethylphenyl] - 1 -oxopropyl] [( 15)- 1 -(4-phenyl- lH-imidazol-2-yl)ethyl] amino] methyl] -2- methoxybenzoic acid, represented by Formula I.

Figure imgf000002_0001

Formula I

Eluxadoline is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

U.S. Patent No. 7,741 ,356 describes a process for the preparation of eluxadoline. U.S. Patent Nos. 7,629,488 and 8,710,256 describe processes for the preparation of intermediates of eluxadoline.

PCT Publication No. WO2009/009480 purportedly discloses forms alpha and beta crystals of eluxadoline and processes thereof. PCT Publication No. WO2009/009480 discloses that form alpha crystals can be prepared by storing the zwitterion of eluxadoline at 0-25% relative humidity (RH) for 3 days and form beta crystals can be prepared by storing the zwitterion of eluxadoline at greater than 60% RH for 3 days.

PCT Publication No. WO2017/015606 purportedly discloses amorphous form, crystalline forms I, II, III and IV, and processes for their preparation and a process for the preparation of form alpha crystal of eluxadoline. Summary of the Invention

The present invention relates to processes for the preparation of a crystalline form of eluxadoline.

Brief Description of the Drawings

Figure 1 depicts an X-Ray Powder Diffraction (XRPD) pattern of a crystalline form of eluxadoline.

Figure 2 depicts an X-Ray Powder Diffraction (XRPD) pattern of a crystalline form of eluxadoline.

Detailed Description of the Invention

The term "about," as used herein, refers to any value which lies within the range defined by a number up to ±10% of the value.

The term "room temperature," as used herein, refers to the temperature in the range of 25°C to 35°C.

The term "contacting", as used herein refers to dissolving, slurrying, stirring, heating, suspending, or combinations thereof.

The term "reaction mass", as used herein refers to suspension, solution, emulsion, or precipitate.

A first aspect of the present invention provides a process for the preparation of a crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 comprising contacting eluxadoline with a solvent.

Eluxadoline used for the preparation of the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 may be prepared by any method provided in the art, for example, the methods as disclosed U.S. Patent No. 7,741,356.

Examples of solvents include methanol, ethanol, iso-propyl alcohol, n-propyl alcohol, n-butanol, methyl iso-butyl ketone, acetone, dichloromethane, ethyl acetate or a mixture thereof.

The preparation of the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out at a temperature of about 35°C to about 75°C. In an embodiment, the preparation of crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out at a temperature of about 35°C to about 70°C. In another embodiment, the preparation of crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out at a temperature of about 40°C to about 65°C. In another embodiment, the preparation of crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out at a temperature of about 45°C to 65°C.

The preparation of the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out for about 4 hours to about 24 hours. In an embodiment, the preparation of crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out for about 8 hours to about 22 hours. In another embodiment, the preparation of crystalline form of eluxadoline as depicted in Figure 1 is carried out for about 10 hours to about 18 hours. In another embodiment, the preparation of crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out for about 12 hours to about 16 hours.

The crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 may optionally be isolated by filtration, decantation, extraction, distillation, evaporation, chromatography, precipitation, concentration, crystallization, centrifugation, and recrystallization. The crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 may be dried using conventional techniques, for example, drying, drying under vacuum, spray drying, suck drying, air drying, or agitated thin film drying.

A second aspect of the present invention provides a process for the preparation of a crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 comprising:

i) contacting eluxadoline with a solvent to obtain a reaction mass;

ii) heating the reaction mass at 35°C to 70°C followed by optional distillation of the solvent to obtain a reaction mass; and

iii) filtering the reaction mass to obtain the crystalline form characterized by

XRPD as depicted in Figure 1.

Eluxadoline used for the preparation of the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 may be prepared by any method provided in the art, for example, the methods as disclosed U.S. Patent No. 7,741,356.

Examples of solvents include methanol, ethanol, iso-propyl alcohol, n-propyl alcohol, n-butanol, methyl iso-butyl ketone, acetone, dichloromethane, ethyl acetate or a mixture thereof. The preparation of the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out for about 4 hours to about 24 hours. In an embodiment, the preparation of the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out for about 5 hours to about 22 hours. In another embodiment, the preparation of the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out for about 10 hours to about 18 hours. In another embodiment, the preparation of crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out for about 12 hours to about 16 hours.

In an embodiment, the reaction mass of step i) is treated with activated carbon.

The crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 may optionally be isolated by filtration, decantation, extraction, distillation, evaporation, chromatography, precipitation, concentration, crystallization, centrifugation, and recrystallization. The crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 may be dried using conventional techniques, for example, drying, drying under vacuum, spray drying, suck drying, air drying, or agitated thin film drying.

A third aspect of the present invention provides a process for the preparation of a crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 comprising:

i) contacting eluxadoline with a solvent to obtain a reaction mass;

ii) heating the reaction mass followed by partial distillation of the solvent to obtain a reaction mass;

iii) filtering the reaction mass to obtain a crystalline form characterized by XRPD as depicted in Figure 2;

iv) storing the crystalline form of step iii) at 25°C to 45°C and relative

humidity at 60% to 95%; and

v) drying to obtain the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1.

Eluxadoline used for the preparation of the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 may be prepared by any method provided in the art, for example, the methods as disclosed U.S. Patent No. 7,741,356. Examples of solvents include methanol, ethanol, iso-propyl alcohol, n-propyl alcohol, n-butanol, methyl iso-butyl ketone, acetone, dichloromethane, ethyl acetate or a mixture thereof.

The heating of the reaction mass of step ii) is carried out at a temperature of about 35°C to 85°C. In an embodiment, the heating of the reaction mass of step ii) is carried out at a temperature of about 38°C to about 82°C.

The partial distillation of the solvent of step ii) is carried out at a temperature of about 35°C to 85°C. In an embodiment, the partial distillation of the solvent of step ii) is carried out at a temperature of about 38°C to about 82°C.

The crystalline form of step iii) is stored for about 1 day to about 7 days. In an embodiment, the crystalline form of step iii) is stored for about 3 days to about 5 days.

The crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 may optionally be isolated by filtration, decantation, extraction, distillation, evaporation, chromatography, precipitation, concentration, crystallization, centrifugation, and recrystallization. The crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 may be dried using conventional techniques, for example, drying, drying under vacuum, spray drying, suck drying, air drying, or agitated thin film drying.

While the present invention has been described in terms of its specific aspects and embodiments, certain modifications and equivalents will be apparent to those skilled in the art, and are intended to be included within the scope of the present invention.

Method

XRPD of the samples was determined by using a PANalytical® instrument; Model X'pert PRO; Detector: X'celerator®.

The following examples are for illustrative purposes only and should not be construed as limiting the scope of the invention in any way.

EXAMPLES

Example 1: Preparation of crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1

Method A: Eluxadoline (10 g) was added to iso-propyl alcohol (300 mL) at 55°C to obtain a reaction mass. The reaction mass was then heated to 60°C to obtain a suspension. The suspension was stirred for 5 hours at 60°C to 66°C, and then cooled to 25°C. The product was filtered, suck dried for 5 minutes and then washed with isopropyl alcohol (20 mL). The solid obtained was suck dried for 5 minutes and then dried under vacuum at 55°C to 60°C for 12 hours to obtain the title compound.

Yield: 7.8 g

Chromatographic Purity: 98.47%

Method B: Eluxadoline (10 g) was added to n-propyl alcohol (300 mL) at 55°C to obtain a reaction mass. The reaction mass was heated to 60°C to obtain a suspension. The suspension was stirred for 5 hours at 60°C to 65 °C and then cooled to 25 °C. The product was filtered, suck dried for 5 minutes and then washed with n-propyl alcohol (20 mL). The solid obtained was suck dried for 5 minutes and then dried under vacuum at 55°C to 60°C for 12 hours to obtain the title compound.

Yield: 7.30 g

Chromatographic Purity: 99.11%

Method C: Eluxadoline (10 g) was added to methyl isobutyl ketone (300 mL) at 55°C to obtain a reaction mass. The reaction mass was heated to 60°C to obtain a suspension. The suspension was stirred for 22 hours at 60°C to 65 °C and then cooled to 25 °C. The product was filtered, suck dried for 5 minutes and then washed with methyl isobutyl ketone (20 mL). The solid obtained was suck dried for 5 minutes and then dried under vacuum at 55°C to 60°C for 12 hours to obtain the title compound.

Yield: 8.95 g

Chromatographic Purity: 97.99%

Method D: Eluxadoline (10 g) was added to ethyl acetate (300 mL) at 55°C to obtain a reaction mass. The reaction mass was heated to 60°C to obtain a suspension. The suspension was stirred for 22 hours at 60°C to 65 °C and then cooled to 25 °C. The product was filtered, suck dried for 5 minutes and then washed with ethyl acetate (20 mL). The solid obtained was suck dried for 5 minutes and then dried under vacuum at 55°C to 60°C for 12 hours to obtain the title compound.

Yield: 8.40 g

Chromatographic Purity: 97.85% Method E: Eluxadoline (10 g) was added to acetone (300 mL) at 55°C to obtain a reaction mass. The reaction mass was heated to 60°C to obtain a suspension. The suspension was stirred for 22 hours at 60°C to 65 °C and then cooled to 25 °C. The product was filtered, suck dried for 5 minutes and then washed with acetone (20 mL). The solid obtained was suck dried for 5 minutes and then dried under vacuum at 55°C to 60°C for 12 hours to obtain the title compound.

Yield: 9.80 g

Chromatographic Purity: 98.34%

Method F: Eluxadoline (10 g) was added to n-butanol (300 mL) at 55°C to obtain a reaction mass. The reaction mass was heated to 60°C to obtain a suspension. The suspension was stirred for 22 hours at 60°C to 65 °C and then cooled to 25 °C. The product was filtered, suck dried for 5 minutes and then washed with n-butanol (20 mL). The solid obtained was suck dried for 5 minutes and then dried under vacuum at 55°C to 60°C for 12 hours to obtain the title compound.

Yield: 7.80 g

Chromatographic Purity: 98.76%

Method G: Eluxadoline (10 g) was added to a mixture of n-propyl alcohol (300 mL) and dichloromethane (400 mL) at 35°C to 38°C to obtain a reaction mass. The reaction mass was heated to 38°C to 40°C to obtain a suspension and then distilled up to a volume of 300 mL at 38°C to 42°C. The suspension was stirred for 3 hours at 50°C to 55°C and then cooled to 25 °C. The product obtained was filtered, and then washed with n-propyl alcohol (20 mL) to obtain a solid. The solid obtained was suck dried for 5 minutes and then dried under vacuum at 55°C to 60°C for 12 hours to obtain the title compound.

Yield: 8.58 g

Chromatographic purity: 99.7%

Method H: Eluxadoline (20 g) was added to a mixture of n-propyl alcohol (10 mL) and methanol (800 mL) at 40°C to 45°C and then stirred for 5 minutes to obtain a clear solution. The solution was filtered through Hyflo® and then washed with methanol (40 mL). The filtrate was heated at 60°C to 65 °C and then distilled up to a volume of 200 mL at 60°C to 65 °C to obtain a suspension. The suspension was stirred for 4 hours at 60°C to 65 °C and then cooled to 5°C to 10°C. The product obtained was filtered and then washed with methanol (40 mL) to obtain a solid. The solid obtained was suck dried for 5 minutes and then dried under vacuum at 55°C to 60°C for 12 hours to obtain the title compound.

Yield: 14.2 g

Chromatographic purity: 99.76%

Method Ha: Eluxadoline (80 g) was added to a mixture of n-propyl alcohol (16 mL) and methanol (3200 mL) at 40°C to 45 °C to get a clear solution. Activated carbon (1.6 g) was added to the solution and stirred for 15 minutes at 40°C to 45 °C. The solution was filtered through Hyflo® followed by micron filter and then washed with methanol (160 mL) at 40°C to 45°C. The filtrate was heated at 60°C to 65°C and then distilled up to a volume of 400 mL at 60°C to 65 °C to obtain a suspension. The suspension was stirred for 4 hours to 5 hours at 60°C to 65°C and then cooled to 0°C to 5°C. The product obtained was filtered and then washed with methanol (160 mL) to obtain a solid. The solid was suck dried for 5 minutes and then dried under vacuum at 55°C to 60°C for 15 hours to obtain the title compound.

Yield: 68.58 g

Chromatographic purity: 99.68%

Method I: Eluxadoline (10 g) was added to isopropyl alcohol (1200 mL) at 72°C to obtain a reaction mass. The reaction mass was heated to 82°C and then distilled up to a volume of 100 mL at 80°C to 82°C to obtain a suspension. The suspension was stirred for 4 hours at 80°C to 82°C and then cooled to 30°C. The product obtained was filtered, suck dried for 5 minutes and then washed with isopropyl alcohol (20 mL). The solid obtained was suck dried for 5 minutes and then dried under vacuum at 60°C to 65 °C for 12 hours. The solid (2.0 g) was stored at 25±2°C/60±5% RH for 3 days and then further dried under vacuum at 55°C to 60°C for 12 hours to obtain the title compound.

Yield: 8.0 g

Method J: Eluxadoline (10 g) was added to ethanol (550 mL) at 70°C to obtain a reaction mass. The reaction mass was heated to 78°C to 79°C and then distilled up to a volume of 70 mL at 78 °C to 80°C to obtain a suspension. The suspension was stirred for 4 hours at 75°C to 79°C and then cooled to 25°C. The product obtained was filtered, suck dried for 5 minutes and then washed with ethanol (20 mL). The solid obtained was suck dried for 5 minutes and then dried under vacuum at 60°C to 65°C for 12 hours. The solid (2.0 g) was stored at 25±2°C/60±5% RH for 3 days and then further dried under vacuum at 55 °C to 60°C for 12 hours to obtain the title compound.

Yield: 7.0 g

Chromatographic Purity: 99.07%

Claims

We Claim:
1. A process for the preparation of a crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 , comprising contacting eluxadoline with a solvent.
2. The process according to claim 1 , wherein the solvent is selected from methanol, ethanol, iso-propyl alcohol, n-propyl alcohol, n-butanol, methyl iso-butyl ketone, acetone, dichloromethane, ethyl acetate or a mixture thereof.
3. The process according to claim 1 , wherein the eluxadoline is contacted with the solvent at a temperature of about 35°C to about 75°C.
4. A process for the preparation of a crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 , comprising
i) contacting eluxadoline with a solvent to obtain a first reaction mass;
ii) heating the reaction mass at 35°C to 70°C followed by optional distillation of the solvent to obtain a second reaction mass; and
iii) filtering the second reaction mass to obtain the crystalline form
characterized by XRPD as depicted in Figure 1.
5. The process according to claim 4, wherein the solvents are selected from methanol, ethanol, isopropyl alcohol, n-propyl alcohol, n-butanol, methyl iso-butyl ketone, acetone, dichloromethane, ethyl acetate or a mixture thereof.
6. A process for the preparation of a crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 comprising
i) contacting eluxadoline with a solvent to obtain a first reaction mass;
ii) heating the first reaction mass followed by partial distillation of the solvent to obtain a second reaction mass;
iii) filtering the second reaction mass to obtain a crystalline form characterized by XRPD as depicted in Figure 2;
iv) storing the crystalline form of step iii) at 25°C to 45°C and relative
humidity at 60% to 95%; and
v) drying to obtain the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1.
7. The process according to claim 6, wherein the solvents are selected from methanol, ethanol, isopropyl alcohol, n-propyl alcohol, n-butanol, methyl iso-butyl ketone, acetone, dichloromethane, ethyl acetate or a mixture thereof.
8. The process according to claim 6, wherein the partial distillation of the solvent of step ii) is carried out at a temperature of about 35°C to 85°C.
9. The process according to claim 6, wherein the crystalline form of step iii) is stored for about 1 day to about 7 days.
PCT/IB2018/053134 2017-04-25 2018-05-04 Processes for the preparation of crystalline form of eluxadoline WO2018198101A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN201711014592 2017-04-25
IN201711014592 2017-04-25

Publications (2)

Publication Number Publication Date
WO2018198101A2 true WO2018198101A2 (en) 2018-11-01
WO2018198101A3 WO2018198101A3 (en) 2019-05-16

Family

ID=63920194

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/053134 WO2018198101A2 (en) 2017-04-25 2018-05-04 Processes for the preparation of crystalline form of eluxadoline

Country Status (1)

Country Link
WO (1) WO2018198101A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10314819B2 (en) 2015-07-23 2019-06-11 Teva Pharmaceuticals International Gmbh Solid state forms of Eluxadoline

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339569B (en) * 2007-07-09 2016-05-31 Furiex Pharmaceuticals Inc Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl- 2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-e thyl]-amino}-methyl)-2-methoxy- benzoic acid.
IS2977B (en) * 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Process for the preparation of intermediates useful in the synthesis of eluxadoline
WO2017015606A1 (en) * 2015-07-23 2017-01-26 Teva Pharmaceuticals International Gmbh Solid state forms of eluxadoline
US20190202793A1 (en) * 2016-06-23 2019-07-04 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
EP3272741A1 (en) * 2016-07-21 2018-01-24 Euticals S.P.A. New stable solvate crystalline forms of eluxadoline
CZ2016548A3 (en) * 2016-09-07 2018-03-14 Zentiva, K.S. Solid state forms of eluxadoline

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10314819B2 (en) 2015-07-23 2019-06-11 Teva Pharmaceuticals International Gmbh Solid state forms of Eluxadoline

Also Published As

Publication number Publication date
WO2018198101A3 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
CN100339384C (en) Crystalline azithromycin, process for manufacture and pharmaceutical compositions thereof
EP2125705B1 (en) Crystalline minocycline base and processes for its preparation
WO2012027543A1 (en) Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof
WO1997049681A1 (en) Polymorphic compounds
CN100363349C (en) Process for preparing 5-'(r)-2-(5,6-diethyl-indian-2-ylamin o)-1-hydroxy-ethyl-8-hydroxy-(1h)-quinolin-2-one salt, useful as an adrenoceptor agonist
US6586576B2 (en) Preparation method of azithromycin hydrates
KR20060052840A (en) Process for producing imide compound
US7491726B2 (en) Crystalline forms of aripiprazole
CN1293661A (en) Pyridazinone hydrochloride compound and method for producing the same
JP2003518056A (en) Novel sertraline hydrochloride polymorphs, methods for their preparation, compositions containing them and methods of using them
CN101139325B (en) 2-(3-cyano-4-isobuoxy phenyl)4-methyl-5-thiazole aminic acid crystal and preparation method thereof
CA1216795A (en) Pharmaceutical compositions having a tranquillizing effect and comprising as an active ingredient at least one n-dihydrothiazolyl-3-quinolein carboxamide derivative
US20140357863A1 (en) Process for preparation of pure linagliptin
US20090298947A1 (en) Polymorphic and amorphous forms of lacosamide and amorphous compositions
WO2005009955A1 (en) Ezetimibe polymorphs
PT2311805E (en) New polymorphic form of bazedoxifene acetate
CN1142820A (en) Crystalline N-acetyl neuraminic acid derivatives and process for their preparation
DE69912773T2 (en) Non-hydrated gabapentin polymorph, production process and use for producing gabapentin pharmaceutical purity.
US8742105B2 (en) Polymorphs of raltegravir potassium
US20060276463A1 (en) Pure levofloxacin hemihydrate and processes for preparation thereof
JP2008179645A (en) Method for obtaining pure enantiomer of pyridazinone derivative
KR101604501B1 (en) Crystal forms of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide and methods for their preparation
US20150376134A1 (en) Process for the preparation of ivacaftor and solvates thereof
OA3019A (en) Process for the preparation of destrogous 2,2 '(ethylenediimino) -di-1-butanol
JP2015534550A (en) Polymorphic forms of ENZALUTAMIDE and their preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18791521

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE